Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.

Qingjiang HuEiji OkiTeppei YamadaTomomi KashiwadaHideto SonodaMasato KataokaHirofumi KawanakaYasushi TsujiAkitaka MakiyamaYuichiro NakashimaMitsuhiko OtaYasue KimuraTomoharu Yoshizumi

Published in: Cancer medicine (2023)

According to the genomic profiling of HER2-positive and negative gastric cancer, several gene alterations in the HER2 pathway may be the potential mechanism underlying trastuzumab resistance. Relative to HER2-positive gastric cancer, HER2-negative gastric tumors with ARID1A mutation may be sensitive to immune checkpoint inhibitors.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
peritoneal dialysis
study protocol
randomized controlled trial
single cell
phase iii
patient reported outcomes
phase ii
tyrosine kinase
risk assessment
transcription factor
human health
genome wide identification